{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:47:14Z","timestamp":1794329234247,"version":"4.9.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.coi.2026.102792","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:28:19Z","timestamp":1779910099000},"page":"102792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["When the lung is at risk: diagnosis, manifestations, and complications of pulmonary sarcoidosis"],"prefix":"10.1016","volume":"101","author":[{"given":"Zehra","family":"Dhanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane DM","family":"Vorselaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-0596","authenticated-orcid":false,"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102792_bib1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102792_sbref2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2026.102792_bib3","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","author":"Baughman","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_bib4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102792_sbref5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(25)00129-8","article-title":"Global epidemiology and burden of interstitial lung disease","volume":"13","author":"Spagnolo","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coi.2026.102792_bib6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.coi.2026.102792_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103397","article-title":"Advanced pulmonary sarcoidosis","volume":"152","author":"Jeny","year":"2025","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2026.102792_bib8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2022.1570","article-title":"Diagnosis and treatment of pulmonary sarcoidosis: a review","volume":"327","author":"Belperio","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2026.102792_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.15-0615","article-title":"Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_bib10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.2.5261.1165","article-title":"Prognosis of intrathoracic sarcoidosis in England","author":"Scadding","year":"1961","journal-title":"BMJ"},{"key":"10.1016\/j.coi.2026.102792_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coi.2026.102792_bib12","first-page":"29","article-title":"Sarcoidosis: epidemiology and prognosis. a 15-year European study","volume":"130","author":"Hillerdal","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.coi.2026.102792_sbref13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/MCP.0000000000000892","article-title":"The role of PET in the management of sarcoidosis","volume":"28","author":"Vender","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coi.2026.102792_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/MCP.0b013e328363ed0d","article-title":"The role of the PET scan in the management of sarcoidosis","volume":"19","author":"Mostard","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coi.2026.102792_bib15","first-page":"123","article-title":"18F-FDG PET as a predictor of pulmonary function in sarcoidosis","volume":"28","author":"Keijsers","year":"2011","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_bib16","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.3390\/jcm12216701","article-title":"Pulmonary function in pulmonary sarcoidosis","volume":"12","author":"Yao","year":"2023","journal-title":"JCM"},{"key":"10.1016\/j.coi.2026.102792_bib17","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.chest.2020.04.074","article-title":"Mixed ventilatory defects in pulmonary sarcoidosis","volume":"158","author":"Kouranos","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_bib18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/000348941011901004","article-title":"Atypical and disparate presentations of laryngeal sarcoidosis","volume":"119","author":"Mayerhoff","year":"2010","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.coi.2026.102792_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/thx.2005.042838","article-title":"Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis","volume":"61","author":"Nunes","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2026.102792_bib20","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1148\/rg.306105512","article-title":"Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation","volume":"30","author":"Criado","year":"2010","journal-title":"Radiographics"},{"key":"10.1016\/j.coi.2026.102792_sbref21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.chest.2023.10.021","article-title":"High-resolution CT scan fibrotic patterns in stage IV pulmonary sarcoidosis","volume":"165","author":"Obi","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/02770903.2012.747204","article-title":"Distinguishing asthma from sarcoidosis: an approach to a problem that is not always solvable","volume":"50","author":"Kalkanis","year":"2013","journal-title":"J Asthma"},{"key":"10.1016\/j.coi.2026.102792_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semdp.2018.09.001","article-title":"Reprint of: the pathology of pulmonary sarcoidosis: update","volume":"35","author":"Ma","year":"2018","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.coi.2026.102792_bib24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/thx.2010.134429","article-title":"Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study","volume":"66","author":"Crawshaw","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2026.102792_bib25","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1183\/09031936.00187410","article-title":"Stage IV sarcoidosis: comparison of survival with the general population and causes of death","volume":"38","author":"Nardi","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib26","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2214\/ajr.174.6.1741751","article-title":"Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function","volume":"174","author":"Abehsera","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.coi.2026.102792_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-022-02094-7","article-title":"Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis","volume":"23","author":"Schimmelpennink","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.coi.2026.102792_bib28","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2026.102792_bib29","first-page":"154","article-title":"Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients","volume":"19","author":"Lewis","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1183\/09031936.00226911","article-title":"Global burden of chronic pulmonary aspergillosis complicating sarcoidosis","volume":"41","author":"Denning","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2026.102792_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02396-2016","article-title":"Chronic pulmonary aspergillosis complicating sarcoidosis","volume":"49","author":"Uzunhan","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168373","article-title":"Outcomes of bronchial artery embolization for life-threatening hemoptysis in patients with chronic pulmonary aspergillosis","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2026.102792_bib34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/ejcts\/ezaa137","article-title":"Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically","volume":"58","author":"Setianingrum","year":"2020","journal-title":"Eur Cardiothorac Surg"},{"key":"10.1016\/j.coi.2026.102792_bib35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1378\/chest.127.2.472","article-title":"Endoluminal stenosis of proximal bronchi in sarcoidosis","volume":"127","author":"Chambellan","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_bib36","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1378\/chest.116.5.1194","article-title":"Airway obstruction in bronchial sarcoidosis","volume":"116","author":"Lavergne","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_sbref37","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib38","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1038\/s41598-019-40030-w","article-title":"Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension","volume":"9","author":"Parikh","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2026.102792_sbref39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/MCP.0000000000001204","article-title":"Evolving management of sarcoidosis in the real world","volume":"31","author":"Culver","year":"2025","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coi.2026.102792_bib40","doi-asserted-by":"crossref","first-page":"6828","DOI":"10.3390\/jcm14196828","article-title":"Immunosuppressive therapies in pulmonary sarcoidosis: a practical, evidence-based review","volume":"14","author":"Dhanani","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102792_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_sbref42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)","volume":"62","author":"Dhooria","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib43","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.coi.2026.102792_bib44","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_bib45","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study","volume":"36","author":"Fang","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_bib46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_bib47","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib48","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000345596","article-title":"Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study","volume":"86","author":"Brill","year":"2013","journal-title":"Respiration"},{"key":"10.1016\/j.coi.2026.102792_sbref49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102792_bib50","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2026.102792_bib51","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S2213-2600(25)00338-8","article-title":"A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders","volume":"14","author":"Wells","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coi.2026.102792_bib54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0000000000000906","article-title":"Hit-hard and early versus step-up treatment in severe sarcoidosis","volume":"28","author":"Vorselaars","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coi.2026.102792_bib55","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102792_bib56","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102792_bib57","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102792_bib58","article-title":"Pirfenidone for Fibrotic Sarcoidosis (PIRFS): results of a double blind placebo controlled feasibility study","volume":"39","author":"Baughman","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_bib59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMra2202819","article-title":"bronchiectasis \u2014 a clinical review","volume":"387","author":"O\u2019Donnell","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102792_bib60","article-title":"Roflumilast (Daliresp\u00ae) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial","volume":"38","author":"Baughman","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_sbref61","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0165-2021","article-title":"WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension","volume":"31","author":"Savale","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.coi.2026.102792_bib62","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial","volume":"145","author":"Baughman","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_bib63","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.chest.2021.07.2162","article-title":"Riociguat for sarcoidosis-associated pulmonary hypertension","volume":"161","author":"Baughman","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_bib64","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000514917","article-title":"The short- and long-term impact of pulmonary rehabilitation in subjects with sarcoidosis: a prospective study and review of the literature","volume":"100","author":"Guber","year":"2021","journal-title":"Respiration"},{"key":"10.1016\/j.coi.2026.102792_sbref65","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1055\/a-2768-2520","article-title":"Advanced Pulmonary Sarcoidosis","volume":"46","author":"Spagnolo","year":"2025","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.coi.2026.102792_bib66","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.healun.2015.08.014","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report\u20142015; focus theme: early graft failure","volume":"34","author":"Yusen","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.coi.2026.102792_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","article-title":"Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: experience from a high volume center","volume":"157","author":"Gangemi","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2026.102792_bib68","doi-asserted-by":"crossref","first-page":"00738","DOI":"10.1183\/23120541.00738-2022","article-title":"Sarcoidosis lung transplantation waitlist mortality, a national registry database study","volume":"9","author":"Fleitas Sosa","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.coi.2026.102792_bib69","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1038\/s41598-018-25144-x","article-title":"White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients","volume":"8","author":"Salamo","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2026.102792_bib70","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/thoraxjnl-2015-207497","article-title":"Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA","volume":"71","author":"Taimeh","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2026.102792_bib71","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03358-2020","article-title":"Lung transplantation for sarcoidosis: outcome and prognostic factors","volume":"58","author":"Le Pavec","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102637","article-title":"Can sarcoidosis be cured?","volume":"96","author":"Spagnolo","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2026.102792_bib73","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01815-2017","article-title":"Sarcoidosis mortality in Sweden: a population-based cohort study","volume":"51","author":"Rossides","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib74","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2026.102792_bib75","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.coi.2026.102792_bib76","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"Swigris","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2026.102792_bib77","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102792_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2026.102792_bib79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coi.2026.102792_bib80","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007595","article-title":"Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain","volume":"96","author":"Ma\u00f1\u00e1","year":"2017","journal-title":"Medicine"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:41:29Z","timestamp":1783932089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":80,"alternative-id":["S0952791526000695"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102792","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When the lung is at risk: diagnosis, manifestations, and complications of pulmonary sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102792"}}